A triplet treatment plus autologous stem-cell transplantation was associated with longer progression... Treatment with teclistamab, a T-cell–redirecting bispecific antibody, led to a “high rate of deep and durable... The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use issued... Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better... The study explored adding daratumumab to RVd and VTd regimens for patients with multiple myeloma... The median PFS with the three-drug combination was higher compared with carfilzomib and dexamethasone alone. Adding ixazomib to this treatment regimen did not improve survival outcomes, according to results of the MUKeight trial A phase I study is underway to assess ALLO-605. Cilta-cel has been approved by the FDA for the treatment of patients with relapsed or refractory multiple myeloma who have ... Teclistamab produced meaningful and durable responses in patients with heavily pretreated relapsed or refractory multiple ... Researchers explored whether population-based screening for MGUS could increase the frequency of patients with multiple ... Post-transplant response-adapted consolidation therapy with Dara-KRd using MRD led to high rates of MRD negativity in ... Daratumumab and hyaluronidase-fihj, in combination with carfilzomib and dexamethasone (Kd), has received U.S. Food and Drug ... Researchers sought to calculate healthcare costs associated with triple class exposure to multiple myeloma. Patients in the trial were treated for lymphoma, leukemia, or multiple myeloma. A study published in Internal Medicine evaluated the safety profile of ixazomib in a cohort of Japanese patients with ... Researchers sought to discern the effect of COVID-19 countermeasures on treatment outcomes in a patient population receiving ...